Targeting epithelial-mesenchymal transition for identification of inhibitors for pancreatic cancer cell invasion and tumor spheres formation

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Polireddy, Kishore ^a   Dong, Ruochen ^a   McDonald, Peter R ^b   Wang, Tao ^a   Luke, Brendan ^a   Chen, Ping ^a   Broward, Melinda ^b   Roy, Anuradha ^b   Chen, Qi ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (BENZYLSULFONYL)INDOLINE; 1 (PHENYLSULFONYL)INDOLINE; 1 [(2 CHLORO 6 FLUOROBENZYL)SULFONYL]INDOLINE; 1 [(2 CHLOROBENZYL)SULFONYL]INDOLINE; 1 [(2 FLUOROBENZYL)SULFONYL]INDOLINE; 1 [(2 METHYLBENZYL)SULFONYL]INDOLINE; 1 [(3 METHYLBENZYL)SULFONYL]INDOLINE; 1 [(4 CHLOROBENZYL)SULFONYL]INDOLINE; 1 [(4 CHLOROPHENYL)SULFONYL]INDOLINE; 2 [2 (5 NITRO 2 THIENYL)VINYL]QUINOLINE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; N,N DIMETHYL 4 [2 (2 QUINOLINYL)VINYL]ANILINE; N,N DIMETHYL 4 [2 (4 QUINOLINYL)VINYL]ANILINE; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CD24 ANTIGEN; EPCAM PROTEIN, HUMAN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MOLECULAR LIBRARY; PROTEIN ZO1; TJP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SNAIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEASIBILITY STUDY; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MIGRATION INHIBITION; PANC 1 CELL LINE; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SCRATCH ASSAY; SPHERE FORMATION ASSAY; TUMOR INVASION; TUMOR SPHEROID; TUMOR STEM CELL ASSAY; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHEMISTRY; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOLECULAR LIBRARY; PANCREAS TUMOR; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANTIGENS, CD24; ANTIGENS, CD44; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL-MESENCHYMAL TRANSITION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; SMALL MOLECULE LIBRARIES; SNAIL FAMILY TRANSCRIPTION FACTORS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84992208894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164811     Document Type: Article

References (63)

1. American Cancer Society. Cancer Facts and Figures 2016. 2016;(Avialable at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/[Accessed Mar 23, 2016]).
2. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol. 2004; 34(5):238-44. Epub 2004/07/03. PMID: 15231857.
3. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 2010; 77(6):606-19. Epub 2010/11/26. doi: 10.1002/msj.20217 PMID: 21105124.
4. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. Epub 2004/03/31. doi: 10.1016/S0140-6736(04)15841-8 S0140-6736(04)15841-8 [pii]. PMID: 15051286.
5. Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist. 2008; 13(5):562-76. Epub 2008/06/03. 13/5/562 [pii] doi: 10.1634/theoncologist.2007-0181 PMID: 18515741.
6. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006; 17 Suppl 5:v7-12. Epub 2006/06/30. 17/suppl-5/v7 [pii] doi: 10.1093/annonc/mdj941 PMID: 16807468.
7. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297(3):267-77. Epub 2007/01/18. 297/3/267 [pii] doi: 10. 1001/jama.297.3.267 PMID: 17227978.
8. Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther. 2010; 10(4):529-40. Epub 2010/04/20. doi: 10.1586/era.10.21 PMID: 20397918.
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6. Epub 2007/04/25. JCO.2006.07.9525 [pii] doi: 10.1200/JCO.2006.07.9525 PMID: 17452677.
10. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010; 59 (11):1527-34. Epub 2010/10/16. 59/11/1527 [pii] doi: 10.1136/gut.2010.216135 PMID: 20947887; PubMed Central PMCID: PMC2981019.
11. Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, et al. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology. 2011; 80(1-2):97-101. Epub 2011/06/17. 000328767 [pii] doi: 10.1159/000328767 PMID: 21677453.
12. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP. 2011;12(2):96-100. Epub 2011/03/10. v12i02a05 [pii]. 21386629.
13. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol. 2011; 12(1):8-9. Epub 2010/11/06. S1470-2045(10)70237-0 [pii] doi: 10.1016/S1470-2045(10)70237-0 PMID: 21050812.
14. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. Epub 2013/10/18. doi: 10.1056/NEJMoa1304369 PMID: 24131140; PubMed Central PMCID: PMCPmc4631139.
15. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-68. Epub 2008/09/12. nrc2499 [pii] doi: 10.1038/nrc2499 PMID: 18784658.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. Epub 2003/03/12. doi: 10.1073/pnas.0530291100 0530291100 [pii]. PMID: 12629218; PubMed Central PMCID: PMC153034.
17. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. Epub 1994/02/17. doi: 10.1038/367645a0 PMID: 7509044.
18. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-9. Epub 2008/05/01. djn123 [pii] doi: 10.1093/jnci/djn123 PMID: 18445819.
19. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8. Epub 2003/10/03. PMID: 14522905.
20. Smalley M, Ashworth A. Stem cells and breast cancer: A field in transit. Nat Rev Cancer. 2003; 3 (11):832-44. Epub 2003/12/12. doi: 10.1038/nrc1212 nrc1212 [pii]. PMID: 14668814.
21. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007; 7(10):791-9. Epub 2007/09/14. nrc2212 [pii] doi: 10.1038/nrc2212 PMID: 17851544.
22. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. Epub 2007/02/07. 67/3/1030 [pii] doi: 10.1158/0008-5472. CAN-06-2030 PMID: 17283135.
23. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008; 26(17):2806-12. Epub 2008/06/10. 26/17/2806 [pii] doi: 10.1200/JCO.2008.16.6702 PMID: 18539958.
24. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and kras transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 2011; 6(1):e16530. Epub 2011/02/10. doi: 10.1371/journal.pone.0016530 PMID: 21304978; PubMed Central PMCID: PMC3031576.
25. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. Epub 2006/10/20. nature05236 [pii] doi: 10.1038/nature05236 PMID: 17051156.
26. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. Epub 2005/04/02. nrc1590 [pii] doi: 10.1038/nrc1590 PMID: 15803154.
27. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458(7239):780-3. Epub 2009/02/nature07733 [pii] doi: 10.1038/nature07733 PMID: 19194462; PubMed Central PMCID: PMC2778612.
28. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006; 98(24):1755-7. Epub 2006/12/21. 98/24/1755 [pii] doi: 10.1093/jnci/djj505 PMID: 17179471.
29. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008; 26(17):2839-45. Epub 2008/06/10. 26/17/2839 [pii] doi: 10.1200/JCO.2007.15. 1829 PMID: 18539962; PubMed Central PMCID: PMC2739000.
30. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A. 2007; 104 (2):618-23. Epub 2007/01/05. 0606599104 [pii] doi: 10.1073/pnas.0606599104 PMID: 17202265; PubMed Central PMCID: PMC1766434.
31. Germain AR, Carmody LC, Morgan B, Fernandez C, Forbeck E, Lewis TA, et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg Med Chem Lett. 2012; 22 (10):3571-4. doi: 10.1016/j.bmcl.2012.01.035 PMID: 22503247.
32. Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, et al. A 1536-well quantitative highthroughput screen to identify compounds targeting cancer stem cells. Journal of biomolecular screening. 2012; 17(9):1231-42. doi: 10.1177/1087057112458152 PMID: 22927676.
33. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-73. Epub 2009/03/06. nrc2620 [pii] doi: 10. 1038/nrc2620 PMID: 19262571.
34. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-59. Epub 2009/08/18. S0092-8674(09)00781-8 [pii] doi: 10.1016/j.cell.2009.06.034 PMID: 19682730.
35. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. Epub 2010/06/10. onc2010215 [pii] doi: 10.1038/onc. 2010.215 PMID: 20531305.
36. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004; 118(3):277-9. Epub 2004/08/06. doi: 10.1016/j.cell.2004.07.011 S0092867404007020 [pii]. PMID: 15294153.
37. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009; 69 (14):5820-8. Epub 2009/07/09. 0008-5472.CAN-08-2819 [pii] doi: 10.1158/0008-5472.CAN-08-2819 PMID: 19584296.
38. Sarkar FH, Li Y, Wang Z, Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009; 64(5):489-500. Epub 2009/10/28. R06095168 [pii]. PMID: 19859039.
39. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009; 69(6):2400-7. Epub 2009/03/12. 0008-5472.CAN-08-4312 [pii] doi: 10.1158/0008-5472.CAN-08-4312 PMID: 19276344; PubMed Central PMCID: PMC2657919.
40. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436(7047):123-7. Epub 2005/07/08. nature03688 [pii] doi: 10.1038/nature03688 PMID: 16001073; PubMed Central PMCID: PMC2784913.
41. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. Epub 2008/05/20. S0092-8674(08)00444-3 [pii] doi: 10.1016/j.cell.2008.03.027 PMID: 18485877; PubMed Central PMCID: PMC2728032.
42. Gupta R, Vyas P, Enver T. Molecular targeting of cancer stem cells. Cell Stem Cell. 2009; 5(2):125-6. Epub 2009/08/12. S1934-5909(09)00340-3 [pii] doi: 10.1016/j.stem.2009.07.006 PMID: 19664981.
43. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nature reviews Molecular cell biology. 2005; 6(8):622-34. doi: 10.1038/nrm1699 PMID: 16025097.
44. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochimica et biophysica acta. 1994; 1198(1):11-26. PMID: 8199193.
45. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998; 392(6672):190-3. Epub 1998/03/27. doi: 10.1038/32433 PMID: 9515965.
46. Wang HG, Huang XD, Shen P, Li LR, Xue HT, Ji GZ. Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. International journal of molecular medicine. 2013; 31(4):967-74. doi: 10.3892/ijmm.2013.1285 PMID: 23440283.
47. Dahlin JL, Walters MA. How to Triage PAINS-Full Research. Assay and drug development technologies. 2016; 14(3):168-74. Epub 2015/10/27. doi: 10.1089/adt.2015.674 PMID: 26496388; PubMed Central PMCID: PMCPmc4841006.
48. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. doi: 10.1021/jm901137j PMID: 20131845.
49. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002; 1(4):287-99. doi: 10.1038/nrd772 PMID: 12120280.
50. Lin Y, Dong C, Zhou BP. Epigenetic regulation of EMT: the Snail story. Curr Pharm Des. 2014; 20 (11):1698-705. PMID: 23888971; PubMed Central PMCID: PMC4005722.
51. Jordaan G, Liao W, Sharma S. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors. BMC cancer. 2013; 13:88. doi: 10.1186/1471-2407-13-88 PMID: 23432814; PubMed Central PMCID: PMC3586366.
52. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007; 98(10):1512-20. Epub 2007/07/25. CAS550 [pii] doi: 10.1111/j.1349-7006.2007.00550.x PMID: 17645776.
53. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2):131-42. Epub 2006/02/24. nrm1835 [pii] doi: 10.1038/nrm1835 PMID: 16493418.
54. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Alexiou D, Kalahanis N, et al. Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer research. 1998; 18(6A):4177-80. PMID: 9891464.
55. Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. Oncogene. 2007; 26 (16):2290-8. doi: 10.1038/sj.onc.1210029 PMID: 17043652.
56. Chetty R, Serra S. Loss of expression of E-cadherin in solid pseudopapillary tumors of the pancreas. Pancreas. 2009; 38(3):338; author reply-9. doi: 10.1097/MPA.0b013e318183d74a PMID: 19307928.
57. Dansranjavin T, Mobius C, Tannapfel A, Bartels M, Wittekind C, Hauss J, et al. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncology reports. 2006; 15(5):1125-31. PMID: 16596173.
58. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. International journal of cancer Journal international du cancer. 2010; 126 (11):2575-83. doi: 10.1002/ijc.24972 PMID: 19839049.
59. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009; 137(1):361-71, 71 e1-5. Epub 2009/04/14. S0016-5085(09)00545-9 [pii] doi: 10.1053/j.gastro.2009.04.004 PMID: 19362090.
60. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature reviews Molecular cell biology. 2014; 15(3):178-96. doi: 10.1038/nrm3758 PMID: 24556840; PubMed Central PMCID: PMC4240281.
61. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007; 7(6):415-28. Epub 2007/05/18. nrc2131 [pii] doi: 10. 1038/nrc2131 PMID: 17508028.
62. Lively S, Waszkowycz B, Harrison M, Farthing C, Johnson K, inventors; Tularik Limited, London (GB), assignee. Serine protease inhibitors. USA2008.
63. Mahboobi S, Sellmer A, Hocher H, Garhammer C, Pongratz H, Maier T, et al. 2-Aroylindoles and 2-Aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors. Journal of medicinal chemistry. 2007; 50(18):4405-18. doi: 10.1021/jm0703136 PMID: 17691763.